Michael Dorogan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Dorogan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Wayne Wesley Harding
Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, New York 10065, United States
2 shared publications - Alexander Deiters
University of Pittsburgh
1 shared publication - Ann M. Decker
RTI International
1 shared publication Ashok Gudipally
Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, NY 10065, United States; Program in Chemistry, CUNY Graduate Center 365 5th Avenue, New York, NY 10016, United States
1 shared publication- Avani Parikh
University of Pittsburgh
1 shared publication Carolyn Rosenblum
University of Pittsburgh
1 shared publication
Latest Publications
- Open Access
- 10 August 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
Targeting Adaptive and Innate Immune Responses with Covalent Aptamers
Covalent aptamers have recently found initial success as tools for fast and selective transfer of labels to target proteins. Here, aptamers targeting protein tyrosine kinase 7 (PTK7) and the mesenchymal-epithelial transition factor (cMet) were functionalized with electrophiles capable of covalently transferring small-molecule immune recruiters. Capitalizing on biotin transfer, aptamers were utilized to trigger activation of universal anti-biotin chimeric antigen receptor (CAR) T cells resulting in selective lysis of PTK7- and cMet-positive cells. Additionally, a cleavable electrophile of 2,4-dinitrophenyl (DNP) hapten transfer was synthesized and utilized for the selective modification of cell surface PTK7 and cMet. The DNP modification elicited the selective activation of complement-dependent cytotoxicity (CDC). These results demonstrate the potential of covalent aptamers as immune-activating and cancer-cell-killing agents.
- 10 August 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
Open AccessTargeting Adaptive and Innate Immune Responses with Covalent Aptamers
Covalent aptamers have recently found initial success as tools for fast and selective transfer of labels to target proteins. Here, aptamers targeting protein tyrosine kinase 7 (PTK7) and the mesenchymal-epithelial transition factor (cMet) were functionalized with electrophiles capable of covalently transferring small-molecule immune recruiters. Capitalizing on biotin transfer, aptamers were utilized to trigger activation of universal anti-biotin chimeric antigen receptor (CAR) T cells resulting in selective lysis of PTK7- and cMet-positive cells. Additionally, a cleavable electrophile of 2,4-dinitrophenyl (DNP) hapten transfer was synthesized and utilized for the selective modification of cell surface PTK7 and cMet. The DNP modification elicited the selective activation of complement-dependent cytotoxicity (CDC). These results demonstrate the potential of covalent aptamers as immune-activating and cancer-cell-killing agents.
- Open Access
- 10 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (24) , 34870-34884
Recent Advances in Dopamine Receptor Ligands as Chemical Biology Tools
Dopamine receptors (DRs) have been implicated in numerous disorders and diseases (e.g., Alzheimer’s disease, Parkinson’s disease, schizophrenia, and substance use disorders) and have served as attractive drug targets for these ailments. Despite their potential clinical utility, the development of selective DR ligands has been challenging due to difficulties in selectivity among the DR subtypes as well as other biogenic amine receptors and poor pharmacokinetic properties. The realization of their full potential necessitates continued advancements in DR ligands as investigative tools. This review aims to highlight the recent developments made in the chemical biology of DR ligands (e.g., bivalent ligands, photoactivatable ligands, photoswitchable probes, and fluorescent probes).
- 10 June 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (24) , 34870-34884
Open AccessRecent Advances in Dopamine Receptor Ligands as Chemical Biology Tools
Dopamine receptors (DRs) have been implicated in numerous disorders and diseases (e.g., Alzheimer’s disease, Parkinson’s disease, schizophrenia, and substance use disorders) and have served as attractive drug targets for these ailments. Despite their potential clinical utility, the development of selective DR ligands has been challenging due to difficulties in selectivity among the DR subtypes as well as other biogenic amine receptors and poor pharmacokinetic properties. The realization of their full potential necessitates continued advancements in DR ligands as investigative tools. This review aims to highlight the recent developments made in the chemical biology of DR ligands (e.g., bivalent ligands, photoactivatable ligands, photoswitchable probes, and fluorescent probes).
- 12 September 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 141, 106862
Fluoroalkoxylated C-3 and C-9 (S)-12-bromostepholidine analogues with D1R antagonist activity
- 12 September 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 141, 106862
Fluoroalkoxylated C-3 and C-9 (S)-12-bromostepholidine analogues with D1R antagonist activity